This study examined the prevalence and predictors of posttraumatic stress disorder (PTSD) symptoms in 70 men and women treated with bone marrow transplantation for cancer. Findings indicated that the number of symptoms present ranged from 0 to a possible high of 17 (M ϭ 3.0, SD ϭ 3.9). As predicted, lower social support and higher avoidance coping 1 month pretransplant predicted greater PTSD symptom severity an average of 7 months posttransplant. These variables remained significant predictors of symptom severity even after accounting for pretransplant levels of psychological distress. Additional analyses indicated the presence of a significant interaction between social support and avoidance coping, with patients high in avoidance coping and low in social support reporting the most severe symptoms. These findings identify patients at risk for psychological disturbance posttransplant and can serve to guide future intervention efforts.
The diagnosis and treatment of cancer can be a traumatic experience with long-lasting psychological effects. Consistent with this view, a number of studies have documented the presence of posttraumatic stress disorder (PTSD), as defined in the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; American Psychiatric Association, 1994), in adult cancer patients (Alter et al., 1996; Andrykowski, Cordova, Studts, & Miller, 1998; Green et al., 1998; Widows, Jacobsen, & Fields, 2000) . Although a relatively small percentage of patients in these studies were found to meet diagnostic criteria for PTSD (range ϭ 3% to 6%), considerable variability is evident in the severity of PTSD symptoms. For example, one study of women with breast cancer reported that the number of PTSD symptoms present ranged from 0 to 15 of a possible 17 .
Research into psychological factors associated with individual differences in PTSD symptomatology among cancer patients has shown that poorer social support Butler, Koopman, Classen, & Spiegel, 1999; Widows et al., 2000) , greater use of avoidance coping (Hampton & Frombach, 2000; Widows et al., 2000) , more precancer stressors Tjemsland, Soreide, & Malt, 1998) , psychiatric disorder prior to cancer diagnosis (Widows et al., 2000) , and more impaired psychosocial functioning prior to cancer diagnosis (Tjemsland et al., 1998) are associated with greater PTSD symptomatology. With one exception (Tjemsland et al., 1998) , these studies are limited methodologically by the use of cross-sectional designs in which the psychological factors are measured concurrently with PTSD symptomatology. Accordingly, it is not possible in many instances to distinguish whether the psychological variables are influencing PTSD symptomatology or vice versa.
To address this limitation, the present study used a longitudinal design in which the psychological variables of interest were assessed before patients underwent bone marrow transplantation (BMT) for treatment for cancer 1 and PTSD symptomatology was assessed approximately 8 months later. We hypothesized that patients who reported greater use of avoidance coping and reduced social support before BMT would report more severe PTSD symptomatology after BMT. This pattern of results would be consistent with prior cross-sectional research Hampton & Frombach, 2000; Widows et al., 2000) and with a social-cognitive-processing model of trauma recovery (Lepore, Silver, Wortman, & Wayment, 1996) . According to this model, greater use of avoidance coping and reduced social support would be expected to provide individuals with fewer opportunities to process or habituate to trauma-related thoughts, images, and memories. To the extent that these factors interfere with cognitive processing, there would be less integration of the traumatic experience into new or preexisting mental schemas and greater likelihood that traumatic material would remain active and capable of precipitating intrusive thoughts and other symptoms of PTSD.
Method

Participants
To be eligible for the current study, patients had to (a) have completed either autologous or allogeneic BMT for cancer, (b) be 18 years of age or older, (c) be able to speak and read English, (d) have completed at least 8 years of formal education, (e) have completed a routine clinical psychosocial evaluation prior to BMT, (f) be approximately 6 months posttransplant, and (g) and have no clinical evidence of disease progression or recurrence at the most recent follow-up visit. Seventy of 103 eligible patients (68%) agreed to participate and provided complete data. There were no significant differences ( p Յ .05) between participants (n ϭ 70) and eligible nonparticipants (n ϭ 33) with regard to age, gender, education, ethnicity, marital status, employment status, type of cancer diagnosis, length of hospitalization, or type of BMT.
Procedure
Approximately 1 month before their scheduled transplants, patients underwent a routine psychosocial assessment conducted with all BMT candidates that included administration of self-report measures of psychological distress, social support, and coping (see below). At 5 months posttransplant, medical records were reviewed to identify individuals who met the remaining eligibility criteria. Letters were sent to eligible patients describing a study of quality-of-life outcomes, of which the current investigation of PTSD symptomatology was one component, and informing them that they would be contacted by telephone to discuss participation. Posttransplant measures that are the focus of this report are described below.
Patients who provided verbal informed consent during the telephone contact were given an appointment for an outpatient research visit. They were also sent a written informed consent form and a questionnaire that included a demographic information form and a self-report measure of PTSD symptomatology (see below). Patients were asked to complete the questionnaire at home in the days just before their outpatient visit. On arriving for their appointment, patients returned the signed consent forms and questionnaires before completing additional clinician-administered measures.
Measures
Demographic data form. Demographic data were obtained posttransplant through use of a standard self-report questionnaire. Variables assessed included age, gender, race and ethnicity, marital status, and education level.
Medical review form. Medical charts were reviewed posttransplant to obtain information about disease and treatment characteristics. Variables assessed included cancer diagnosis, type of BMT, and dates of admission and discharge for BMT.
Coping Responses Inventory (CRI). The CRI (Moos, 1993), a selfreport measure of coping responses to stressful life circumstances, was administered during the pretransplant evaluation. Participants rated how often (0 ϭ not at all, 3 ϭ fairly often) they had used each of the 48 coping responses listed in the CRI in dealing with their cancer and its treatment.
These ratings were used to compute scores for scales that have been labeled Logical Analysis, Positive Reappraisal, Seeking Guidance and Support, Problem Solving, Cognitive Avoidance, Acceptance or Resignation, Seeking Alternative Rewards, and Emotional Discharge. The first four scales are conceptualized as measuring approach coping, and the latter four scales are conceptualized as measuring avoidance coping (Moos, 1993) . Scores for the four approach subscales were summed to yield a total approach coping score (Cronbach's ␣ ϭ .83), and scores for the four avoidance subscales were summed to yield a total avoidance coping score (Cronbach's ␣ ϭ .78).
Profile of Mood States (POMS).
The POMS (McNair, Lorr, & Droppleman, 1992) , a 65-item measure of psychological distress, was also administered during the pretransplant evaluation. Participants indicated how well each item described how they had been feeling during the past week (0 ϭ not at all, 4 ϭ extremely). As in previous research with cancer patients (Carver et al., 1993) , scores on the Tension-Anxiety, DepressionDejection, and Anger-Hostility subscales were summed to yield a total distress score (Cronbach's ␣ ϭ .93).
Interpersonal Support Evaluation List-Short Form (ISEL-SF).
The ISEL-SF (Peirce, Frone, Russell, & Cooper, 1996) , a brief measure of social support, was also completed during the pretransplant evaluation. The full-length version of the ISEL (Cohen, Mermelstein, Kamarck, & Hoberman, 1985) consists of 40-items that respondents rate in terms of how true or false the statements are of them (1 ϭ completely false, 4 ϭ completely true). The ISEL-SF retains 5 items each from the original Tangible Support, Appraisal Support, and Belonging Support subscales. A total social support score was calculated by summing ratings for all 15 items (Cronbach's ␣ ϭ .81).
PTSD Checklist-Civilian Version (PCL-C).
The PCL-C (Weathers, Litz, Herman, Huska, & Keane, 1993), a 17-item self-report measure that reflects DSM-IV symptom criteria for PTSD, was completed during the posttransplant evaluation. Participants were instructed to consider their experience with cancer and its treatment and to rate how much they had been bothered by each symptom during the past month (1 ϭ not at all, 3 ϭ moderately, 5 ϭ extremely). The PCL-C yields a total score as well as subscale scores for Intrusion, Avoidance-Numbing, and Arousal. According to the scale developers (Weathers et al., 1993) , respondents are considered likely to meet DSM-IV criteria for PTSD if (a) they endorse (i.e., rate as "moderately" or greater) one or more intrusion symptoms, three or more avoidance-numbing symptoms, and two or more arousal symptoms in accordance with DSM-IV criteria or (b) they obtain a total score of 50 or greater. Previous research with cancer patients Widows et al., 2000) indicates that both scoring methods possess high diagnostic efficiency relative to interview-based methods of diagnosing PTSD (range ϭ .90 -.98). The PCL-C can also be used as a continuous measure of the severity of PTSD symptomatology. A total PTSD severity score was created by summing the 17 symptom ratings (Cronbach's ␣ ϭ .93).
Results
Study participants ranged in age from 23 to 65 years (M ϭ 48, SD ϭ 9). The majority of participants were female (76%), White non-Hispanic (93%), currently married (64%), and had some schooling beyond high school (60%). Eighty-three percent of the sample underwent autologous transplantation, and 17% underwent allogeneic transplantation. The majority of patients were diagnosed with breast cancer (67%), followed by leukemia (12%), multiple myeloma (13%), and lymphoma (8%). Mean length of hospitalization was 24 days (SD ϭ 12; range ϭ 16 -95). Participants averaged 6.9 months postdischarge (SD ϭ 1.2; range ϭ 5.1-10.6) at the time of follow-up assessment.
The mean score on the PCL-C for the sample was 29.4 (SD ϭ 11.2; range ϭ 17-70). Participants reported an average of 3.0 symptoms (SD ϭ 3.9; range ϭ 0 -17) as evidenced by moderate or greater intensity ratings on individual PCL-C items. Using the cutoff method (total PCL-C score Ն 50), we identified 4 participants (6%) as likely to merit a formal diagnosis of PTSD. Using the symptom method (at least moderate ratings of one intrusion symptom, three avoidance-numbing symptoms, and two arousal symptoms), we identified 6 participants (9%) as likely to merit a formal diagnosis of PTSD.
Correlations between PTSD symptom severity and demographic, medical, and psychological variables appear in Table 1 . There were no significant ( p Ͻ .05) associations between any of the demographic and medical variables assessed and PTSD symptom severity posttransplant. As predicted, greater use of avoidance coping and reduced social support prior to transplant were significantly related ( p Յ .001) to greater PTSD symptom severity posttransplant.
2 Greater psychological distress prior to transplant was also significantly related ( p Ͻ .0001) to more severe PTSD symptomatology posttransplant. Approach coping was not significantly related to PTSD symptom severity ( p ϭ .63).
A multiple regression analysis was performed to identify the variance in PTSD symptomatology accounted for by the three psychological variables measured prior to transplant for which significant results were obtained. Psychological distress was entered into the analysis first to provide a conservative test of the predictive value of social support and avoidance coping. As shown in Table 2 , this variable accounted for 30% of the variability in PTSD symptom severity ( p Ͻ .0001). The two remaining variables were allowed to enter the analysis using a forward selection method. Social support accounted for 6% additional variability ( p ϭ .01) followed by avoidance coping, which accounted for 5% of the remaining variability in PTSD symptom severity ( p ϭ .02).
Additional regression analyses were undertaken to determine the presence of interactions among the three psychological variables. A significant interaction was found between social support and avoidance coping ( p ϭ .005). This interaction accounted for 7% of the variability in PTSD symptom severity not already explained by psychological distress, social support, and avoidance coping (see Table 2 ). On the basis of methods developed by Aiken and West (1991) , analyses were conducted to characterize the nature of the interaction (see Figure 1) . Specifically, regression analyses were performed to determine whether the simple slope of equations using social support to predict PTSD symptom severity differed significantly from zero at specified levels of avoidance coping. At a high level of avoidance coping (1 SD above the group mean), there was evidence of a significant relationship between PTSD symptom severity and level of social support, t(66) ϭ Ϫ4.55, p Ͻ .0001. As shown in Figure 1 , participants who were high in avoidance coping and low in social support were predicted to report more severe PTSD symptomatology than participants who were high in both avoidance coping and social support. A different pattern emerged at a low level of avoidance coping (1 SD below the group mean), where there was no evidence of a significant relationship between level of social support and PTSD symptom severity, t(66) ϭ 0.53, p ϭ .60.
Discussion
Depending on the PCL-C scoring method used, 6% to 9% of participants in the current study were considered likely to merit a DSM-IV diagnosis of PTSD. These prevalence rates are similar to those previously reported for cancer patients treated with BMT (M. Y. Smith, Redd, DuHamel, Vickberg, & Ricketts, 1999; Widows et al., 2000) . Although a relatively small percentage of the sample appeared to meet diagnostic criteria for PTSD, there was evidence that PTSD symptom severity varied considerably among study participants. The number of symptoms that participants reported being present at moderate or greater intensity on the PCL-C ranged from 0 to 17 of a possible 17. Furthermore, total scores on the PCL-C ranged from a low of 17 to a high of 70 out of a possible range of 17 to 85. Similar variability in PTSD symptom severity has been reported in prior research in which the PCL-C was administered to samples of cancer patients (Cordova et al., 1995; Jacobsen et al., 1998; Widows et al., 2000) .
Demographic and medical factors assessed in the current study failed to demonstrate significant univariate associations with PTSD symptom severity. In contrast, at least two previous studies 2 To evaluate the possibility that the observed relation between avoidance coping and PTSD symptom severity may be due to overlapping item content, we conducted an additional analysis using a revised PCL-C total score that excluded the five Avoidance subscale items. Results indicated that avoidance coping remained significantly correlated with PTSD symptom severity (r ϭ .40, p Ͻ .001). of cancer patients have reported that younger age (Cordova et al., 1995; Green et al., 1998; Tjemsland et al., 1998) and less education (Cordova et al., 1995; Jacobsen et al., 1998) are associated with greater PTSD symptom severity. The absence of significant results for age in the current study may be due to restrictions in the age range of potential participants. BMT is typically not performed with elderly individuals because of the increased mortality risk (Peters, 1997) and, consistent with this practice, there were no participants in the present study above 65 years of age. In contrast, all three previous studies reporting positive associations involved patients undergoing other forms of cancer treatment and included individuals greater than 65 years of age. The absence of a significant association between education and PTSD severity cannot be explained on the same basis, as participants' education levels varied from 9 to 20 years. Although our finding is inconsistent with results reported in two previous studies, it should be noted that one other study of cancer patients also found education to be unrelated to PTSD symptom severity (Widows et al., 2000) . In contrast to the pattern of results for demographic and medical factors, psychological factors assessed in the current study accounted for a sizable amount of the variability in PTSD symptomatology. Univariate analyses indicated that social support and avoidance coping each accounted for 14% or more of the variability in PTSD symptom severity. Moreover, social support and avoidance coping continued to account for significant variability in PTSD symptom severity (6% and 5%, respectively) after controlling for pretransplant levels of psychological distress. Not surprisingly, pretransplant levels of psychological distress accounted for a substantial amount of the variability in PTSD symptom severity (30%). This result is similar to findings from one of the few other longitudinal investigations of PTSD symptomatology in cancer patients. In this study (Tjemsland et al., 1998) , women who reported prior to breast cancer surgery the presence of one or more negative life events or more impaired psychosocial functioning in the past year were found to have greater PTSD symptomatology 1 year later.
These findings regarding avoidance coping and social support confirm and extend prior research. Greater use of avoidant-coping strategies (e.g., escape-avoidance, distancing, and denial) has repeatedly been shown to be associated with increased PTSD symptomatology in other populations, including veterans and crime and accident victims (Blake, Cook, & Keane, 1992; Bryant & Harvey, 1995; Harrison & Kinner, 1998; Sutker, Davis, Uddo, & Ditta, 1995; Wolfe, Keane, Kaloupek, Mora, & Wine, 1993) . Similarly, greater social support has been shown to be associated with decreased PTSD symptomatology in veterans, burn victims, and community samples (Davidson, Hughes, Blazer, & George, 1991; Green, Grace, Lindy, Gleser, & Leonard, 1990; King, King, Fairbank, Keane, & Adams, 1998; Perry, Difede, Musngi, Frances & Jacobsberg, 1992) .
Previous studies with cancer patients have also shown that higher levels of avoidance coping (Hampton & Frombach, 2000; Widows et al., 2000) and lower levels of social support Butler et al., 1999; Widows et al., 2000) are associated with greater PTSD symptomatology. However, unlike these studies in which avoidance coping, social support, and PTSD symptomatology were measured concurrently, findings from the current study are predictive in nature. That is, levels of avoidance coping and social support were measured prior to transplant and were found to predict levels of PTSD symptomatology approximately 8 months later. Thus, the current study provides the strongest empirical support to date for the view that avoidance coping and social support play a causal role in the development of PTSD symptomatology in cancer patients.
Findings from the present study also indicated that the effects of avoidance coping and social support on PTSD symptom severity are interactive. That is, there was evidence that social support had a greater impact on PTSD symptom severity in individuals more reliant on avoidance coping. Among these individuals, a high level of social support was estimated to be associated with 50% less PTSD symptom severity than a low level of social support. These results can be understood in terms of a social-cognitive model of trauma recovery (Lepore et al., 1996) , in which the cognitive processing of a traumatic event through social interactions is viewed as an important component of psychological recovery. Consistent with this model, results suggested that the presence of a supportive social environment could encourage individuals who might otherwise rely on avoidant forms of coping to cognitively process traumatic material. For example, supportive friends or relatives may have been able to elicit discussion of traumatic aspects of the cancer experience from individuals who would be unlikely to initiate such discussions on their own. By so doing, these supportive environments may serve to prevent or reduce the development of PTSD symptomatology in at-risk individuals.
The use of a longitudinal design in the present study represents a notable methodologic improvement over most previous research on PTSD symptomatology in cancer patients. Nevertheless, several limitations remain. One limitation involves the lack of data on the presence and severity of PTSD symptomatology in the pretransplant period. Although regression analysis indicated that social support and avoidance coping remained significant predictors of PTSD symptomatology after controlling for pretransplant levels of psychological distress, their predictive value above and beyond pretransplant levels of PTSD symptomatology is unknown. A second limitation involves the inclusion of only a single follow-up assessment. Inclusion of multiple follow-up assessments would have allowed for identification of the time course of PTSD symp- tom development and the stability of PTSD symptoms in the posttransplant period. Participation bias is a third limitation. Thirty-two percent of individuals eligible for the current study were not represented in the final sample. Although these nonparticipants did not differ from participants on any of the demographic or medical variables that were assessed, we cannot rule out a possible relationship between nonparticipant status and PTSD symptom severity. Indeed, it is quite plausible that individuals experiencing greater PTSD symptomatology would be more likely to decline participation in a desire to avoid unpleasant reminders of their cancer treatment.
Avoidance coping and lack of social support were found to be important risk factors for development of PTSD symptomatology following BMT. In addition to confirming and extending prior research, these findings have both theoretical and clinical implications. In terms of theory, results support the utility of a socialcognitive model of trauma recovery. Consistent with this model, there was evidence that the presence of a supportive social environment may moderate the impact of cognitive processes likely to impede psychological recovery in traumatized individuals. In terms of clinical practice, results yield a psychological profile of BMT candidates at increased risk for PTSD symptomatology following treatment completion. In addition to their usefulness in identifying at-risk individuals, these findings suggest the use of cognitive-behavioral interventions, used effectively against PTSD in other populations (Meadows & Foa, 2000) , in which avoidance of traumatic material is challenged in an emotionally supportive environment. In light of accumulating evidence that many cancer patients experience PTSD symptomatology for months or even years following treatment completion, there is a compelling need to identify treatments that can effectively address these disturbing symptoms.
